CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Ventana Medical Systems announced the global launch of its BRAF V600E immunohistochemistry test to detect the BRAF V600E mutation in a variety of tumors. The test, launched as a U.S. class I exempt/CE-IVD product, is designed to detect the most frequent BRAF mutation, V600E, which has been found to play a key role in a variety of cancers, including colorectal cancer.
The Ventana BRAF V600E (VE1) mouse monoclonal primary antibody IHC assay is the result of the company’s exclusive license agreement with the German Cancer Research Center and the University Hospital Heidelberg, Germany, to commercialize the novel IHC primary antibody that detects the V600E mutated BRAF protein. It is a fully automated IHC test, providing lab professionals and pathologists with a highly sensitive and specific standardized testing method for assessing the BRAF V600E mutation in tissue.
The assay is designed to perform on all Ventana Benchmark IHC platforms with the OptiView DAB IHC Detection Kit, providing easy interpretation and seamless integration into a laboratory’s workflow.
Ventana Medical Systems , 520-887-2155